Lowenstein Represents Crown Laboratories in Merger Agreement with Revance Therapeutics, Inc.

Lowenstein Sandler represented longtime client Crown Laboratories, Inc. a privately held, global innovative leader in the skincare industry, in a proposed merger agreement with Revance Therapeutics, Inc. (NASDAQ: RVNC), a biotechnology company aimed at setting the new standard in healthcare with innovative aesthetic and therapeutic offerings.

Under the terms of the agreement, which has been unanimously approved by Revance's Board of Directors, Crown will commence a tender offer to acquire all outstanding shares of Revance's common stock for $6.66 per share in cash, representing a total enterprise value of $924 million.

Upon completion of the transaction, Crown Laboratories expects to be one of the leading global aesthetics and skincare companies in an attractive, high-growth market, with an industry-leading portfolio of 10+ cutting-edge skin health and aesthetic brands, and one of the largest distribution footprints in skincare across medical, retail and e-commerce channels.

The transaction is expected to close by year end.

Crown is a portfolio company of Hildred Capital Management, LLC.

Lowenstein has also represented Crown in the acquisitions of Eclipse MedCorp LLC; global skincare company StriVectin®; North American rights to Keri® from GlaxoSmithKline(GSK); and a portfolio of top-rated GSK products, including: PanOxyl®, a leading acne wash; Sarna, an anti-itch lotion; Zeasorb, an anti-fungal prevention product; Desenex®, an anti-fungal powder; and Mineral Ice®, a leading pain-relieving gel.

The Lowenstein deal team included Sam E. Khan, Brianna M. Ferrante, Santino G. Pelusi. Adam Gakin, Nicola E. Perzichilli, Kimberly E. Lomot, Angela Raleigh, Megan Monson, Jessica I. Kriegsfeld, Nicholas G. Mehler, Matthew P. Hintz, Robert J. Paradiso, Alyssa D'Antonio, Erich J. Kaletka, Eric Jesse, Paul F. Giannoglou, James C. Shehan, Manali Joglekar, Mark S. Heinzelmann, Mitchell McDonald, Amani Taha, and Tala Ismail.